Slingshot Insights

Catalyst

Slingshot members are tracking this event:

FDA Approves Odefsey for Treatment of HIV-1

Source Link:: http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle&ID=2144886

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

JNJ

100%

GILD

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details The FDA approved the single tablet regimen Odefsey (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) for the treatment of HIV-1 infection. Emtricitabine and tenofovir alafenamide are Gilead developments and rilpivirine is from Johnson & Johnson.

http://investors.gil...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Mar 01, 2016

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Fda Approval, Odefsey, Emtricitabine, Rilpivirine, Tenofovir Alafenamide, Hiv-1